English
sibrafiban
Sign in to saveAlso known as Xubix
Sibrafiban (Ro 48–3657, proposed brand name Xubix) is the double prodrug of Ro-44-3888, which is a platelet aggregation inhibitor. It was being developed for secondary prevention of arterial thrombosis following unstable angina pectoris and acute myocardial infarction (MI). On August 6, 1999, Hoffmann-La Roche announced that the preliminary results from Phase III clinical trials had not shown that sibrafiban was better than aspirin in preventing recurrent ischemic events in patients with acute coronary syndrome. The development of sibrafiban was terminated.
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 420.201
Show 4 more facts
- chemical formula
- C₂₀H₂₈N₄O₆
- canonical SMILES
- CCOC(=O)COC1CCN(CC1)C(=O)C(C)NC(=O)C2=CC=C(C=C2)C(=NO)N
- isomeric SMILES
- CCOC(=O)COC1CCN(CC1)C(=O)[C@H](C)NC(=O)C2=CC=C(C=C2)/C(=N/O)/N
- subject has role
- platelet aggregation inhibitors
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Sibrafiban (Ro 48–3657, proposed brand name Xubix) is the double prodrug of Ro-44-3888, which is a platelet aggregation inhibitor. It was being developed for secondary prevention of arterial thrombosis following unstable angina pectoris and acute myocardial infarction (MI). On August 6, 1999, Hoffmann-La Roche announced that the preliminary results from Phase III clinical trials had not shown that sibrafiban was better than aspirin in preventing recurrent ischemic events in patients with acute coronary syndrome. The development of sibrafiban was terminated.
== See also == Tirofiban
Excerpted from Wikipedia’s “sibrafiban” article, available under the CC BY-SA 4.0 licence.